NCT06052852 2025-11-17Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesBolt Biotherapeutics, Inc.Phase 1 Terminated17 enrolled
NCT05259696 2025-08-20GLIMMER-01Palleon Pharmaceuticals, Inc.Phase 1/2 Completed69 enrolled 13 charts
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled
NCT04460456 2022-06-30A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid TumorsSilverback TherapeuticsPhase 1 Unknown58 enrolled